Reunion Neuroscience (REUN) announced that it has appointed psychiatrist Fred Grossman, D.O., FAPA, to its Board of Directors. Dr. Grossman has over two decades of experience in clinical development and medical affairs, pharmacovigilance and health outcomes across a variety of products, including biologics and small molecules. Dr. Grossman previously served as the Chief Medical Officer at Empyrean Neuroscience, Mesoblast Limited (MESO) and NeuroRx Pharma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on REUN:
- Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors
- Reunion Neuroscience announces abstract accepted for 2023 ASCP annual meeting
- Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting
- Reunion Neuroscience downgraded to Hold from Speculative Buy at Stifel
- Mindset Pharma to defend against lawsuit filed by Reunion Neurosciences